| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations (NCT02296112) | Vanderbilt-Ingram Cancer Center | 2015-01-01 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery (NCT02166255) | Wake Forest University Health Sciences | 2014-12-01 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery (NCT02203604) | CINJRegulatory | 2014-11-26 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic (NCT02094872) | Yale University | 2014-05-01 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery (NCT01835184) | National Cancer Institute (NCI) | 2013-05-01 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery (NCT01701037) | Vanderbilt-Ingram Cancer Center | 2013-01-01 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery (NCT01748747) | Mayo Clinic | 2012-10-01 |
| FDG-PET in Advanced Melanoma (NCT02236546) | Vanderbilt-Ingram Cancer Center | 2012-05-01 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma (NCT02507076) | Albert Einstein College of Medicine | 2012-04-01 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib (NCT01519427) | National Cancer Institute (NCI) | 2012-01-01 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery (NCT01533948) | Roswell Park Cancer Institute | 2012-01-01 |
| Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma (NCT01321437) | University of California, Irvine | 2011-12-01 |
| RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery (NCT01216787) | National Cancer Institute (NCI) | 2010-09-01 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma (NCT01026324) | National Cancer Institute (NCI) | 2009-09-01 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00470470) | National Cancer Institute (NCI) | 2007-04-01 |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma (NCT00436605) | National Cancer Institute (NCI) | 2006-12-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma (NCT00089063) | National Cancer Institute (NCI) | 2004-06-01 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma (NCT00085189) | University of Southern California | 2004-05-01 |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma (NCT00003895) | National Cancer Institute (NCI) | 1999-04-01 |